Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;80(Suppl 1):S160-S166.
doi: 10.1016/j.mjafi.2023.03.001. Epub 2023 May 16.

Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting carcinoma prostate (CaP) in patients with lower urinary tract symptoms and raised serum prostate-specific antigen (sr.PSA)

Sejal Mehta  1 , Mrunal Ketkar  2 , D K Jain  3
Affiliations

Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting carcinoma prostate (CaP) in patients with lower urinary tract symptoms and raised serum prostate-specific antigen (sr.PSA)

Sejal Mehta et al. Med J Armed Forces India. 2024 Dec.

Abstract

Background: Carcinoma prostate (CaP) is second most common cancer and sixth leading cause of cancer-related mortality among men worldwide. Prostate-specific antigen (sr. PSA) levels are prostate specific, not cancer specific. Therefore, finding non-invasive novel markers that can detect clinically significant CaP for preventing unnecessary biopsies is needed. Relation between host inflammatory responses and tumour has been increasingly recognized in various carcinomas. Many follow-up studies used neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with sr. PSA level for CaP detection in India. The present study explored the use of these biomarkers in predicting CaP in patients with lower urinary tract symptoms (LUTS).

Methods: This prospective observational analytical study included 220 patients who underwent prostate biopsy for LUTS and suspected CaP between 2019 and 2021. Pearson's correlation (r) was used to find association between various attributes. Receiver operating characteristic curve analysis was performed to determine cut-off values and find sensitivity, specificity, positive and negative predictive value of NLR and PLR. P-value <0.05 was considered statistically significant (α = 5%).

Results: Out of 263 patients, 43 were excluded. Among remaining 220 study patients, 166 had BPH and 54 CaP. Median values of NLR and PLR were significantly higher in CaP patients. There was a strong positive correlation noted between NLR, PLR, and CaP groups. Areas under receiver operating characteristic curve of NLR (p = 0.001) and PLR (p < 0.001) for predicting CaP were statistically significant, with cut-off values of >3.44 and > 165.96, respectively.

Conclusion: In present study, we found significant increase in NLR and PLR in CaP patients. These parameters could be useful as pre-prostate biopsy predictors of CaP and help avoid unnecessary biopsies.

Keywords: Biomarkers; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Preprostate biopsy predictors; Prostatic cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have none to declare.

Similar articles

See all similar articles

References

    1. Jain S., Saxena S., Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014 Aug 29;2:596–605. - PMC - PubMed
    1. Shariat S.F., Roehrborn C.G. Using biopsy to detect CaP. Rev Urol. 2008 Fall;10(4):262–280. - PMC - PubMed
    1. Adhyatma K.P., Warli S.M. Diagnostic value of platelet-to-lymphocyte ratio in CaP. Open Access Maced J Med Sci. 2019 Apr 13;7(7):1093–1096. - PMC - PubMed
    1. Masuda H., Mikami K., Otsuka K., et al. Validation of the effectiveness of neutrophil-to-lymphocyte ratio (NLR) as a predictive factor in patients undergoing prostate biopsy with prostate specific antigen (PSA) between 4.0 and 10.0ng/ml. In Vivo. 2021 May-Jun;35(3):1641–1646. - PMC - PubMed
    1. Amayo A., Obara W. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate. East Afr Med J. 2004 Jan;81(1):22–26. - PubMed

LinkOut - more resources